Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...
Medscape4d
B-Cell Depleting Drug Shines in IgG4-Related Disease
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
The American Journal of Managed Care13d
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or ...
Autolus secures FDA approval for CAR-T cell therapy use in ALL
Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...
Monthly Prescribing Reference10d
Aucatzyl Approved for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...